Clinical significance and management of low-level HIV viremia in the era of integrase strand transfer inhibitors.

Autor: Shi J; Affiliated Hangzhou Xixi Hospital Zhejiang University School of Medicine, Hangzhou, PR China., Ying G; Affiliated Hangzhou Xixi Hospital Zhejiang University School of Medicine, Hangzhou, PR China., Zheng R; Affiliated Hangzhou Xixi Hospital Zhejiang University School of Medicine, Hangzhou, PR China., Zhang Z; Affiliated Hangzhou Xixi Hospital Zhejiang University School of Medicine, Hangzhou, PR China.
Jazyk: angličtina
Zdroj: HIV medicine [HIV Med] 2024 Mar; Vol. 25 (3), pp. 361-369. Date of Electronic Publication: 2023 Nov 22.
DOI: 10.1111/hiv.13585
Abstrakt: Background: People living with HIV (PLWH) and receiving antiretroviral therapy (ART) have a goal of achieving and maintaining viral suppression; however, the existence of PLWH that show events of low-level viremia (LLV) between 50 and 1000 copies/mL and with different virological consequences have been observed. Moreover, some reports indicate that LLV status can lead to residual immune activation and inflammation, leading to a higher occurrence of non-AIDS-defining events (nADEs) and other adverse clinical outcomes. Until now, however, published data have shown controversial results that hinder understanding of this phenomenon's actual cause(s) and origin(s). Integrase strand transfer inhibitors (INSTIs)-based therapies could lead to lower LLV over time and, therefore, more effective virological control.
Objectives: This review aims to assess recent findings to provide a view of the clinical significance and management of low-level HIV viremia in the era of INSTIs.
(© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)
Databáze: MEDLINE
Externí odkaz: